Subscribe to Packaging Digest
RSS
Reprints/License
Print
Email

Packaging problems spur Novartis recall

Posted by John Kalkowski -- Packaging Digest, 1/9/2012 9:27:22 AM

NovartisSwiss pharmaceutical giant Novartis AG announced the voluntarily recalls for certain over-the-counter products in the U.S. following consumer complaints of chipped and broken pills as well as mixed tablets due to inconsistent bottle packaging line clearance practices. The company has recalled some of the lots of Excedrin, NoDoz, Bufferin and Gas-X Prevention products from wholesalers and retailers.

 

 The company added that the recall is being conducted with the knowledge of the U.S. Food and Drug Administration (FDA) and Novartis Consumer Health, Inc., that produces a variety of products mainly for the U.S. market.

 "We are committed to a single quality standard for the entire Novartis Group and we are making the necessary investments and committing the right resources to ensure these are implemented across our entire network," CEO Joseph Jimenez said in a statement.

 

 Parsippany, New Jersy-based Novartis Consumer Health recalled all lots of select bottle packaging configurations of Excedrin and NoDoz products with expiry dates of Dec. 20, 2014 or earlier as well as Bufferin and Gas-X Prevention products with expiry dates of December 20, 2013. The company said the action is taken as a precautionary measure, and there have been no related adverse event reports received.

 

The company noted that the chipping and mixing of different products in the same bottle could result in consumers taking the incorrect product and receiving a higher or lower strength than intended or receiving an unintended ingredient.

The recall comes of the back of the recent voluntary suspension of operations and shipments from Novartis Consumer Health, Inc.'s Lincoln, Nebraska-based facility in order to accelerate maintenance and other improvement activities at the facility. The company said it will gradually resume operations at the facility after implementation of planned improvements and in agreement with the FDA.

 

The company noted that it will take a one-time charge currently estimated at $120 million in the fourth quarter of 2011, relating to the recalls and improvement work at the Lincoln facility.

 

For more information, visit the Novartis website by clicking here.


(RTT News)

 

RSS
Reprints/License
Print
Email
Talkback
Related Content

No related content found.

»MORE

Canon Resource Center

Featured Company


Most Recent Resources

Advertisement
Related Content
  • Blogs
  • Photos

Tom Szaky

Green Terratory

Tom Szaky
January 3, 2012
The most wasteful time of the year
The amount of waste generated by U.S. consumers leaps by 25 percent around the...
More

KC Boxbottom

Adventures in Packaging

KC Boxbottom
December 21, 2011
The case of the crazy case
“KC,” she exclaimed, “my codes are wandering all over my...
More

Lisa McTigue Pierce

Digestibles

Lisa Pierce
December 8, 2011
3D packaging: no funny glasses required (unless you want)
Judged the Flexible Packaging Assn awards earlier this week. Fun, fun, fun. This...
More

KC Boxbottom

Adventures in Packaging

KC Boxbottom
November 30, 2011
The case of the sparky conveyor
It was a ho-hum kind of day and I was relaxing with my favorite magazine,...
More

VIEW ALL BLOGS RSS

Advertisement
Qpack ad mkt module
About Us   |   Advertising Info   |   Site Map   |   Contact Us   |   FREE Subscriptions   |   RSS
 © 2012 UBM Canon. All rights reserved.
Use of this Web site is subject to its Terms of Use | Privacy Policy